Rajeev Raghavan, MD
Internal Medicine · Houston, TXNPI 1851599740
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.1%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 36 manufacturers reported payments, led by Lilly USA, LLC at 37.2% of the total. Reporting peaked in 2024 at $77,772 and has fallen 62.7% since, to $29,028 in 2025. Among internal medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 317 payments — averaging $498.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$59K
- GSK$56K
- Boehringer Ingelheim$14K
- Bayer$14K
- Travere Therapeutics, Inc.$8K
- Novartis$4K
- plus $4K from 30 others
Across 34 payments — averaging $2377.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Travere Therapeutics, Inc.$81K
What the payments were for
- Consulting fees$56,40836%
- Speaking & faculty fees$85,48854%
- Travel & lodging$2,7892%
- Food & beverage$7,1345%
- Education$6,1614%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 69 | $58,805 |
| GSK | 44 | $55,837 |
| Boehringer Ingelheim | 17 | $14,224 |
| Bayer | 21 | $13,699 |
| Travere Therapeutics, Inc. | 23 | $7,752 |
| Novartis | 15 | $3,625 |
| Calliditas Therapeutics US Inc. | 19 | $636 |
| AstraZeneca(2 entities) | 11 | $590 |
| Amgen(2 entities) | 22 | $555 |
| Mallinckrodt Hospital Products Inc. | 11 | $350 |
| Johnson & Johnson | 8 | $207 |
| Vifor Pharma, Inc. | 5 | $205 |
| Otsuka America Pharmaceutical, Inc. | 7 | $192 |
| Outset Medical Inc | 1 | $139 |
| AbbVie | 6 | $129 |
| Fresenius USA Marketing, Inc. | 2 | $120 |
| Aurinia Pharma U.S., Inc. | 5 | $107 |
| Recor Medical Inc | 4 | $99 |
| Baxter Healthcare | 1 | $98 |
| ANI Pharmaceuticals, Inc. | 3 | $72 |
| Abbott | 3 | $64 |
| Ardelyx, Inc. | 3 | $62 |
| Kaneka Medical America LLC | 1 | $57 |
| Akebia Therapeutics Inc | 2 | $45 |
| Exact Sciences | 2 | $42 |
| Dexcom, Inc. | 2 | $38 |
| Inspire Medical Systems, Inc. | 1 | $37 |
| Novo Nordisk | 1 | $27 |
| Apellis Pharmaceuticals, Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Sanofi | 1 | $23 |
| Paratek Pharmaceuticals, Inc. | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Inari Medical, Inc. | 1 | $19 |
| Philips North America LLC | 1 | $18 |
| Antares Pharma, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$157,979 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 15 | $21,853 |
| FarxigaDapagliflozin Propanediol | 21 | $11,436 |
| EliquisApixaban | 11 | $7,027 |
| Nifedipine ErNifedipine | 20 | $808 |
| Olmesartan Medoxomil | 23 | $737 |
| Tamsulosin Hcl | 30 | $473 |
| Chlorthalidone | 27 | $373 |
| Atorvastatin Calcium | 55 | $350 |
| Furosemide | 55 | $302 |
| Losartan Potassium | 39 | $226 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $223 |
| Gabapentin | 22 | $214 |
| Calcitriol | 12 | $197 |
| Torsemide | 12 | $158 |
| Lisinopril | 30 | $151 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $14,224 | $21,85315 claims |
| AstraZenecaFarxiga | $590 | $11,43621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Houston
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
- Krina PatelHouston$255K
- Nicholas ShortHouston$247K
- Naveen PemmarajuHouston$230K
- Mariana Chavez MacgregorHouston$188K
- Shumei KatoHouston$180K
- Sukhdeep BasraHouston$168K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.